Aleksandr I. Karachunskiy

Aleksandr I. Karachunskiy

Auto-generated profile, based on publicly available information

Aleksandr I. Karachunskiy

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EMEkaterina Mikhailova
Ekaterina Mikhailova
OIOlga Illarionova
Olga Illarionova
AKAlexander Y Komkov
Alexander Y Komkov
EZElena Zerkalenkova
Elena Zerkalenkova
IMIlgar Z. Mamedov
Ilgar Z. Mamedov
APAlexander popov
Alexander popov
We aimed to develop an antibody panel and data analysis algorithm for multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease (MRD) detection in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CD19-directed therapy. The development of the approach, which was adapted for the case of possible CD19 loss, was based on the additional B-lineage marker expression data obtained from a study of primary BCP-ALL patients, an analysis of the immunophenotypic changes that occur during blinatumomab or CAR-T therapy, and an analysis of very early CD19-negative normal BCPs. We have developed a single-tube 11-color panel for MFC-MRD detection. CD22- and iCD79a-based primary B-lineage gating (preferably consecutive) was recommended. Based on patterns of antigen expression changes and the relative expansion of normal CD19-negative BCPs, guidelines for MFC data analysis and interpretation were established. The suggested approach was tested in comparison with the molecular techniques: IG/TR gene rearrangement detection by next-generation sequencing (NGS) and RQ-PCR for fusion-gene transcripts (FGTs). Qualitative concordance rates of 82.8% and 89.8% were obtained for NGS-MRD and FGT-MRD results, respectively. We have developed a sensitive and reliable approach that allows MFC-MRD monitoring after CD19-directed treatment, even in the case of possible CD19 loss.

23 February 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
LPLudmila Papusha
Ludmila Papusha
MZMargarita Zaytseva
Margarita Zaytseva
APAgnesa Panferova
Agnesa Panferova
ADAlexander E. Druy
Alexander E. Druy
AVAndge Valiakhmetova
Andge Valiakhmetova
RPRoger J Packer
Roger J Packer
Infant hemispheric high-grade gliomas (iHGGs) constitute a biologically and clinically distinct subgroup of pediatric HGGs. One defining hallmark of iHGG is rearrangement of receptor tyrosine kinase either ALK, ROS1, NTRK1,2,3, or MET. The ROS1-positive iHGGs are an exceptionally rare tumor subtype with a relatively poor prognosis.1 The most typical ROS1 fusion partner for such tumors is GOPC.2 Here we describe two extremely rare cases of iHGG with ROS1 fused with the Zinc Finger CCHC-Type Containing 8 (ZCCHC8) gene. Although these patients had major differences in clinical presentation, MRI characteristics, and histopathology, both children were successfully treated with the NTRK/ROS1/ALK inhibitor entrectinib. To date, only two ZCCHC8:ROS1-positive gliomas were described; one of the patients received targeted therapy.3,4

6 March 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
FGfor the ALL-MB study group
for the ALL-MB study group
AKAlexander Karachunskiy
Alexander Karachunskiy
GTGesche Tallen
Gesche Tallen
JRJulia Roumiantseva
Julia Roumiantseva
SLSvetlana Lagoiko
Svetlana Lagoiko
GHGünter Henze
Günter Henze
Favorable outcomes were achieved for children with acute lymphoblastic leukemia (ALL) with the first Russian multicenter trial Moscow–Berlin (ALL-MB) 91. One major component of this regimen included a total of 18 doses of weekly intramuscular (IM) native Escherichia coli-derived asparaginase (E. coli-ASP) at 10000 U/m2 during three consolidation courses. ASP was initially available from Latvia, but had to be purchased from abroad at substantial costs after the collapse of Soviet Union. Therefore, the subsequent trial ALL-MB 2002 aimed at limiting costs to a reasonable extent and also at reducing toxicity by lowering the dose for standard risk (SR−) patients to 5000 U/m2 without jeopardizing efficacy.

Verified
Journal Article
Open access
PDF file
ASAlexandra Semchenkova
Alexandra Semchenkova
EMEkaterina Mikhailova
Ekaterina Mikhailova
IDIrina Demina
Irina Demina
JRJulia Roumiantseva
Julia Roumiantseva
AKAlexander Karachunskiy
Alexander Karachunskiy
APAlexander popov
Alexander popov
Multicolor flow cytometry (MFC) is a key method for assessing measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL). However, very few approaches were developed for MRD in T-cell ALL (T-ALL). To identify MRD markers suitable for T-ALL, we analyzed the expression of CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD34, CD45, CD48, CD56, CD99, and HLA-DR in T-ALL patients at diagnosis. The median fluorescence intensities (MFIs) of surface CD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99, and CD16+CD56 were also evaluated at Day 15 and the end-of-induction (EOI). The MFC data from 198 pediatric T-ALL patients were analyzed retrospectively. At diagnosis, the most common antigens were identified, and the MFI of T-lineage antigens in blasts was compared to that in T lymphocytes. At follow-up, the MFIs of the proposed MRD markers were compared to those observed at diagnosis. The most common T-ALL antigens were CD7 (100.0%), intracellular CD3 (100.0%), CD45 (98.5%), and CD5 (90.9%). The MFIs of T-lineage antigens in blasts differed significantly from those in T lymphocytes. By the EOI, a substantial modulation of sCD3, CD4, CD5, CD7, CD8, and CD45 was observed. CD48 and CD99 were the most stable markers. The proposed MRD markers (sCD3, CD4, CD5, CD7, CD8, CD45, CD48, CD99, CD16+CD56) enabled MFC-MRD monitoring in virtually all T-ALL patients.

Verified
Journal Article
Open access
PDF file
IDIrina Demina
Irina Demina
ADAya Dagestani
Aya Dagestani
ABAleksandra Borkovskaia
Aleksandra Borkovskaia
ASAlexandra Semchenkova
Alexandra Semchenkova
OSOlga Soldatkina
Olga Soldatkina
APAlexander Popov
Alexander Popov
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) develops from very early cells with the potential for both T-cell and myeloid differentiation. The ambiguous nature of leukemic blasts in ETP-ALL may lead to immunophenotypic alterations at relapse. Here, we address immunophenotypic alterations and related classification issues, as well as genetic features of relapsed pediatric ETP-ALL. Between 2017 and 2022, 7518 patients were diagnosed with acute leukemia (AL). In addition to conventional immunophenotyping, karyotyping, and FISH studies, we performed next-generation sequencing of the T-cell receptor clonal repertoire and reverse transcription PCR and RNA sequencing for patients with ETP-ALL at both initial diagnosis and relapse. Among a total of 534 patients diagnosed with T-cell ALL (7.1%), 60 had ETP-ALL (11.2%). Ten patients with ETP-ALL experienced relapse or progression on therapy (16.7%), with a median time to event of 5 months (ranging from two weeks to 5 years). Most relapses were classified as AL of ambiguous lineage (n = 5) and acute myeloid leukemia (AML) (n = 4). Major genetic markers of leukemic cells remained unchanged at relapse. Of the patients with relapse, four had polyclonal leukemic populations and a relapse with AML or bilineal mixed-phenotype AL (MPAL). Three patients had clonal TRD rearrangements and relapse with AML, undifferentiated AL, or retention of the ETP-ALL phenotype. ETP-ALL relapse requires careful clinical and laboratory diagnosis. Treatment decisions should rely mainly on initial examination data, taking into account both immunophenotypic and molecular/genetic characteristics.

20 December 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ASAlexandra Semchenkova
Alexandra Semchenkova
OIO. I. Illarionova
O. I. Illarionova
IDI. A. Demina
I. A. Demina
EMEkaterina Mikhailova
Ekaterina Mikhailova
EZE. A. Zerkalenkova
E. A. Zerkalenkova
APAlexander popov
Alexander popov
Flow cell sorting is an advanced laboratory technique that combines the analytical capabilities of flow cytometry with the ability to isolate pure cell populations from heterogeneous samples. It has tremendous potential both for fundamental research and laboratory diagnosis. For example, the combination of cell sorting and molecular genetic studies can be used to clarify ambiguous results of acute leukemia immunophenotyping obtained both at diagnosis and during minimal residual disease monitoring. These guidelines are based on years of experience in incorporating cell sorting into the diagnostic and monitoring processes at the Leukemia Immunophenotyping Laboratory of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. They include methods used for the confirmation of flow cytometry data depending on the type of leukemia, the stage of a flow cytometry assay and previous therapy. They also describe cell sorting algorithms for disease diagnosis and the specifics of sample preparation for cell sorting in different molecular genetic studies.